^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Melanoma

    Related cancers:
    1d
    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1, N=56, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation
    |
    Keytruda (pembrolizumab) • MQ710
    1d
    An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) (clinicaltrials.gov)
    P2, N=267, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2029 --> Nov 2032 | Trial primary completion date: Sep 2029 --> Nov 2032
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    1d
    Extracellular vesicles derived from pro-inflammatory M1 macrophages induce an inflammatory and invasive phenotype in melanoma cells. (PubMed, Cell Commun Signal)
    Our findings suggest that M1 EVs promote tumor-associated inflammation in melanoma cells through NF-ĸB signaling. This underscores the pivotal role of EV-mediated macrophage-tumor cell communication in cancer progression.
    Journal
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL1B (Interleukin 1, beta)
    1d
    A Rare Case of Primary Bladder Lymphoepithelial Carcinoma. (PubMed, Arch Esp Urol)
    The patient remained recurrence-free at 11 months of follow-up after gemcitabine bladder infusion chemotherapy, arterial drug-infusion embolization, systemic chemotherapy, and immunotherapy.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • ALPP (Alkaline Phosphatase, Placental) • SALL4 (Spalt Like Transcription Factor 4) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • TCF4 (Transcription Factor 4)
    |
    gemcitabine
    1d
    Synergistic antiproliferative and pro-apoptotic activity of dacarbazine combined with 2-aminoethyl dihydrogen phosphate in melanoma cells. (PubMed, Biomed Pharmacother)
    In summary, the dacarbazine-2-AEH2P combination exhibits synergistic pharmacodynamic activity that enhances cytotoxicity through coordinated modulation of proliferative and apoptotic pathways. These findings highlight its potential as a promising strategy to improve chemotherapeutic efficacy and overcome resistance in melanoma treatment.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
    |
    dacarbazine
    1d
    Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study (clinicaltrials.gov)
    P1, N=3, Terminated, Mayo Clinic | Trial completion date: Jan 2026 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2026 --> Feb 2025; low/slow accrual
    Trial completion date • Trial termination • Trial primary completion date
    |
    IMC-001
    1d
    Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Sep 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301)
    1d
    VSV-02 Compassionate Use in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Recruiting, The First Affiliated Hospital of Xinxiang Medical College
    New P1 trial
    1d
    The syntenic long non-coding RNA DANCR is an essential regulator of zebrafish development and a human melanoma oncogene. (PubMed, PLoS Genet)
    It is dynamically expressed across multiple different cell types in the developing embryo, transcriptionally activated by mitfa during early zebrafish development and it regulates genes involved in cell death. Our work suggests that cancer-critical lncRNAs such as DANCR, expressed from similar regions in vertebrate genomes, may control related genes and processes involved in both embryonic development and tumorigenesis across species.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MITF (Melanocyte Inducing Transcription Factor) • DANCR (Differentiation Antagonizing Non-Protein Coding RNA)
    1d
    Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis. (PubMed, Target Oncol)
    Tebentafusp for patients with HLA-A*02:01-positive mUM is associated with improved survival outcomes and manageable toxicity. These findings support tebentafusp as the standard of care for this patient population.
    Retrospective data • Review • Journal
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02:01
    |
    Kimmtrak (tebentafusp-tebn)
    2d
    Combination therapy improves survival prognosis in anti-MDA5-antibody-positive dermatomyositis patients: a single-center retrospective study. (PubMed, Front Immunol)
    This study aimed to compare the efficacy and safety of calcineurin inhibitor monotherapy (CNI) versus combination therapy [CNI and tofacitinib (TOF) or cyclophosphamide (CTX)] as initial immunosuppressive regimens for MDA5+DM. In our study, combination therapy may improve survival prognosis in MDA5+ DM patients. Nevertheless, vigilant monitoring for opportunistic infections during treatment is essential.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8) • IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    cyclophosphamide • tofacitinib